Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, colorectal 1

2652 - Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer

Date

09 Sep 2017

Session

Gastrointestinal tumours, colorectal 1

Topics

Cytotoxic Therapy;  Colon and Rectal Cancer

Presenters

Yoshito Komatsu

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

Y. Komatsu1, A. Takashima2, T. Denda3, M. Gamoh4, I. Iwanaga5, H. Shimodaira6, M. Nakamura7, T. Yamaguchi8, H. Takahashi9, K. Kobayashi10, M. Tsuda11, Y. Kobayashi12, H. Baba13, M. Kotake14, C. Ishioka6, A. Sato15, S. Yuki16, S. Morita17, S. Takahashi18, K. Shimada19

Author affiliations

  • 1 Cancer Center, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 2 Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo/JP
  • 3 Gastroenterology, Chiba Cancer Center, 260-8717 - Chiba/JP
  • 4 Medical Oncology, Osaki Citizen Hospital, 989-6183 - Osaki/JP
  • 5 Medical Oncology, Japanese Red Cross Kitami Hospital, 090-0026 - Kitami/JP
  • 6 Medical Oncology, Tohoku University Hospital, 9808675 - Sendai/JP
  • 7 Aizawa Comprehensive Cancer Center, Aizawa Hospital, 390-8510 - Matsumoto/JP
  • 8 Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 113-0021 - Tokyo/JP
  • 9 Clinical Oncology, Japanese Red Cross Ishinomaki Hospital, 986-8522 - Ishinomaki/JP
  • 10 Medical Oncology, Showa University Northern Yokohama Hospital, 224-8503 - Yokohama/JP
  • 11 Medical Oncology, Hyogo Cancer Center, 673-8558 - Akashi/JP
  • 12 Medical Oncology, Kushiro Rosai Hospital, 085-8533 - Kushiro/JP
  • 13 Surgery, Kumamoto University, 860-8556 - Kumamoto/JP
  • 14 Surgery, Kouseiren Takaoka Hospital, 933-8555 - Takaoka/JP
  • 15 Medical Oncology, Hirosaki University Graduate School of Medicine, 036-8562 - Hirosaki/JP
  • 16 Gastroenterology And Hepatology, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 17 Biomedical Statistics And Bioinformatics, Graduate School of Medicine, Kyoto University, 606-8507 - Kyoto/JP
  • 18 Medical Oncology, Tohoku University Hospital, 980-8575 - Sendai/JP
  • 19 Medical Oncology, Showa University Kouto-Toyosu Hospital, 135-8577 - Tokyo/JP
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2652

Background

Combination therapy with oral fluoropyrimidine and irinotecan (CPT-11) has not yet been established as first-line treatment for metastatic colorectal cancer (mCRC). However, several studies of S-1 and CPT-11 plus bevacizumab (Bmab) combination therapy have shown promising efficacy in mCRC, suggesting the potential to replace mFOLFOX6 or CapeOX plus Bmab. We performed a randomized phase 3 trial to determine whether S-1 and CPT-11 plus Bmab is non-inferior or superior to mFOLFOX6 or CapeOX plus Bmab in terms of progression-free survival (PFS).

Methods

The TRICOLORE trial was a randomized, open-label, phase 3 trial. Chemotherapy-naïve patients with mCRC were randomized to receive either mFOLFOX6 or CapeOX plus Bmab (group A) or S-1 and CPT-11 plus Bmab (group B; 3-week regimen: 7.5 mg/kg Bmab, 150 mg/m2 CPT-11 on day 1, and 40 − 60 mg S-1 twice daily for 2 weeks, followed by a 1-week rest; or 4-week regimen: 5 mg/kg Bmab, 100 mg/m2 CPT-11 on days 1 and 15, and 40 − 60 mg S-1 twice daily for 2 weeks, followed by a 2-week rest). The primary endpoint was PFS. The non-inferiority margin was a hazard ratio (HR) of 1.25 based on the assumption of a median PFS of 11/12 months in group A/group B (power 0.85, 1-sided alpha 0.025). The primary tumor RAS status of patients consented to submit tissue sample were centrally analyzed.

Results

A total of 487 patients were enrolled from June 2012 to September 2014. Data were analyzed after confirming >374 events as planned. All demographic factors were well balanced. Median PFS was 10.8 months in group A and 14.0 months in group B (HR 0.85, 95% CI: 0.70–1.03, p 

Conclusions

S-1 and CPT-11 plus Bmab was non-inferior to mFOLFOX6 or CapeOX plus Bmab with respect to PFS and has now become a recommended 1st-line treatment for mCRC irrespective of RAS status.

Clinical trial identification

UMIN000007834 2012/05/11

Legal entity responsible for the study

The Tokyo Cooprative Oncology Group

Funding

The Tokyo Cooprative Oncology Group (with funding from Taiho)

Disclosure

Y. Komatsu: Other substantive relationships: Taiho Pharmaceutical, Lilly, MSD, Ono Pharmaceutical, Novartis, Chugai Pharma, Yakult, Merck Serono, Pfizer, Bayer. A. Takashima: Corporate-sponsored research: Taiho Pharmaceutical, Gilead Sciences, Merck Serono. M. Gamoh: Corporate-sponsored research: Taiho Pharmaceutical, Gilead Sciences, Merck Serono. H. Shimodaira: Corporate-sponsored research: Taiho, Eisai, Bayer. H. Baba: Advisory board or Board of directors: Taiho Pharmaceutical Co., Ltd.; corporate-sponsored research: Taiho Pharmaceutical Co., Ltd. C. Ishioka: Mochida, Kyowa-K, Eisai, Chugai, Tsumura, Novartis, Merck Serono, Daiichi Sankyo, Takeda, Nihon-Kayaku, Yakult, Taiho, Ono, Astellas, Asahi Kasei, Kissei, Bristol-Myers Squibb, Mochida, Chugai, Novartis, Lilly, Bayer. A. Sato: Advisory board or Board of directors: Taiho Pharmaceutical Co., Ltd. Chugai Pharma Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd.; corporate-sponsored research: Taiho Pharmaceutical Co., Ltd.Chugai Pharma Co., Ltd. S. Yuki: Speakers’ bureau: Chugai Pharmaceutical, Eli Lilly Japan, Bayer Yakuhin, Takeda Pharmaceutical, Taiho Pharmaceutical, Merck Serono. S. Morita: Corporate-sponsored research: Taiho; honorarium: Taiho. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.